As of Thursday close, ResMed Inc.’s (NYSE:RMD) stock was down -$4.83, moving down -3.42 percent to $136.29. The average number of shares traded per day over the past five days has been 1,627,140 shares. 1 time new highs have been achieved over the past 5 days, with a -$11.35 fall in that time frame. In the last twenty days, the average volume was 1,746,010, while in the previous 50 days, it was 1,447,134.
Since last month, RMD stock retreated -16.17%. Shares of the company fell to $136.22 on 09/21/23, the lowest level in the past month. A 52-week high of $243.52 was reached on 04/28/23 after having rallying from a 52-week low of $141.01. Since the beginning of this year, RMD’s stock price has dropped by -34.52% or -$71.84, and marked a new high 9 times. However, the stock has declined by -44.03% since its 52-week high.
RMD stock investors should be aware that ResMed Inc. (RMD) stock had its last reported insider trading activity 7 days ago on Sep 15. Farrell Michael J., the Chief Executive Officer of the company, disposed of 5,675 shares for $146.35 on Sep 15. It resulted in a $830,514 divestment by the insider. Rider Michael J sold 25 shares at an average price of $161.15 on Sep 01. The insider now owns 7,408 shares following the transaction. On Aug 15, Chief Executive Officer Farrell Michael J. sold 5,675 shares at $183.20 apiece. The transaction was valued at $1,039,647.
Valuation Metrics
Right now, ResMed Inc. (RMD) has a P/E ratio of about 22.38. The stock’s beta is 0.54. Besides these, the trailing price-to-sales (P/S) ratio of 4.82, the price-to-book (PB) ratio of 4.85, and the price-to-cash flow ratio of 36.39 may also be considered.
The latest dividend of $0.48 per share was paid out, which is 9.09% more than last year’s $0.44. On Thursday August 3 2023, a $0.04 dividend increase was announced.
Financial Health
In the three months ended June 29, ResMed Inc.’s quick ratio stood at 1.80, while its current ratio was 3.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.35, and the total debt-to-equity ratio was 0.35. On the profitability front, the trailing twelve-month gross margin is 55.80% percent. In the year ended June 29, EBITDA margin amounted to 31.96%, whereas operating margins totaled 27.30%. Based on annual data, RMD earned $2.36 billion in gross profit and brought in $4.22 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 17.00%. Return on equity (ROE) for the past 12 months was 23.60%.
In ResMed Inc.’s quarter-end financial report for June 29, it reported total debt of $1.43 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. RMD’s revenue rose 17.79% to $1.11 billion during the quarter, while net income inched up to $1.11 billion. While analysts expected ResMed Inc. to report $1.69 quarterly earnings, the actual figure was $1.6 per share, beating the consensus estimate by -5.30%. During the quarter, the company generated $330.47 million in EBITDA. The liabilities of ResMed Inc. were 2.62 billion at the end of its most recent quarter ended June 29, and its total debt was $1.58 billion. The value of shareholders’ equity is $147.07 million.
Technical Picture
This quick technical analysis looks at ResMed Inc.’s (RMD) price momentum. With a historical volatility rate of 25.70%, the RSI 9-day stood at 16.26% on 21 September.
With respect to its five-day moving average, the current ResMed Inc. price is down by -7.69% percent or -$11.35. At present, RMD shares trade -15.87% below its 20-day simple moving average and -43.44% percent below its 100-day simple moving average. However, the stock is currently trading approximately -37.16% below its SMA50 and -41.48% below its SMA200.
Stochastic coefficient K was 1.62% and Stochastic coefficient D was 2.76%, while ATR was 4.12. Given the Stochastic reading of 0.28% for the 14-day period, the RSI (14) reading has been calculated as 19.35%. As of today, the MACD Oscillator reading stands at -4.86, while the 14-day reading stands at -7.62.
Analyst Ratings
Needham upgraded its rating on ResMed Inc. (NYSE: RMD) to a Buy in a note to investors on September 06, 2023. The analysts firm previously had a Hold rating on the stock.ResMed Inc. (RMD) has been rated Overweight by analysts. According to 0 brokerage firms, RMD is a sell, and 5 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 5 analysts rate ResMed Inc. stock as buy, with 13 recommending it as overweight.
With a median target price of $225.37, the current consensus forecast for the stock is $170.00 – $275.00. Based on these forecasts, analysts predict ResMed Inc. (RMD) will achieve an average price target of $223.00.
